H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Co-Diagnostics (CODX) today and set a price target of $20.00. The company’s shares closed last Monday at $10.45.
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -19.8% and a 27.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Aerpio Pharmaceuticals.
Co-Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See today’s analyst top recommended stocks >>
Based on Co-Diagnostics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $1.75 million. In comparison, last year the company had a GAAP net loss of $1.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company’s products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules.
Read More on CODX:
